• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Ki67、VEGF 和 p53 与肝移植患者肝癌复发的相关性。

Correlationship between Ki67, VEGF, and p53 and Hepatocellular Carcinoma Recurrence in Liver Transplant Patients.

机构信息

Department of Hepatobiliary Disease, The 900th Hospital of the People's Liberation Army Joint Service Support Force (Dongfang Hospital), Xiamen University, Fuzhou, Fujian, China.

Department of Oncology, The 900th Hospital of the People's Liberation Army Joint Service Support Force (Dongfang Hospital), Xiamen University, Fuzhou, Fujian, China.

出版信息

Biomed Res Int. 2021 Apr 15;2021:6651397. doi: 10.1155/2021/6651397. eCollection 2021.

DOI:10.1155/2021/6651397
PMID:33954191
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8064788/
Abstract

BACKGROUND AND AIMS

Patients with hepatocellular carcinoma (HCC) who undergo orthotopic liver transplantation (OLT) are at risk for posttransplant tumor recurrence. The aim of this study was to evaluate the correlation between the expression of Ki67, VEGF, and p53 in HCC and clinicopathological characteristics of HCC patients, as well as their predictive value for HCC recurrence after OLT.

METHODS

60 patients who underwent OLT and were found to have HCC in the liver explant. The expression of Ki67, VEGF, and p53 in HCC was detected by immunohistochemistry.

RESULTS

Ki67 was associated with the tumor number and the grade of differentiation at baseline. VEGF was associated with the diameter and number of tumors, tumor differentiation, and lymph node metastasis. p53 was associated with the tumor diameter and tumor encapsulation. The expression of Ki67, VEGF, and p53 in HCC was correlated with the tumor recurrence after OLT, respectively. Among them, VEGF was an independent predictor for tumor recurrence after OLT.

CONCLUSION

Ki67, VEGF, and p53 are associated with the recurrence of HCC after OLT. VEGF independently predicts the recurrence of HCC.

摘要

背景与目的

接受原位肝移植(OLT)的肝细胞癌(HCC)患者存在移植后肿瘤复发的风险。本研究旨在评估 HCC 中 Ki67、VEGF 和 p53 的表达与 HCC 患者临床病理特征的相关性,以及它们对 OLT 后 HCC 复发的预测价值。

方法

60 例接受 OLT 并在肝移植标本中发现 HCC 的患者。采用免疫组织化学法检测 HCC 中 Ki67、VEGF 和 p53 的表达。

结果

Ki67 与基线时的肿瘤数量和分化程度有关。VEGF 与肿瘤直径和数量、肿瘤分化和淋巴结转移有关。p53 与肿瘤直径和肿瘤包膜有关。HCC 中 Ki67、VEGF 和 p53 的表达与 OLT 后肿瘤复发有关。其中,VEGF 是 OLT 后肿瘤复发的独立预测因子。

结论

Ki67、VEGF 和 p53 与 OLT 后 HCC 的复发有关。VEGF 独立预测 HCC 的复发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0453/8064788/f2e0c93b4d68/BMRI2021-6651397.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0453/8064788/349bb60a3f03/BMRI2021-6651397.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0453/8064788/7ab94a009c7d/BMRI2021-6651397.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0453/8064788/00082b48b913/BMRI2021-6651397.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0453/8064788/abc4ca41b9eb/BMRI2021-6651397.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0453/8064788/f2e0c93b4d68/BMRI2021-6651397.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0453/8064788/349bb60a3f03/BMRI2021-6651397.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0453/8064788/7ab94a009c7d/BMRI2021-6651397.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0453/8064788/00082b48b913/BMRI2021-6651397.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0453/8064788/abc4ca41b9eb/BMRI2021-6651397.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0453/8064788/f2e0c93b4d68/BMRI2021-6651397.005.jpg

相似文献

1
Correlationship between Ki67, VEGF, and p53 and Hepatocellular Carcinoma Recurrence in Liver Transplant Patients.Ki67、VEGF 和 p53 与肝移植患者肝癌复发的相关性。
Biomed Res Int. 2021 Apr 15;2021:6651397. doi: 10.1155/2021/6651397. eCollection 2021.
2
Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma.p53、Bcl-2、VEGF、Ki67和PCNA在肝细胞癌中的表达及其预后意义
J Gastrointestin Liver Dis. 2008 Dec;17(4):411-7.
3
p53, Ki-67, and serum alpha feto-protein as predictors of hepatocellular carcinoma recurrence in liver transplant patients.p53、Ki-67及血清甲胎蛋白作为肝移植患者肝细胞癌复发的预测指标
Mod Pathol. 2005 Nov;18(11):1498-503. doi: 10.1038/modpathol.3800458.
4
Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma.凋亡和血管生成因子在评估肝细胞癌预后中的临床价值。
J Cancer Res Clin Oncol. 2006 Sep;132(9):547-55. doi: 10.1007/s00432-006-0097-5. Epub 2006 Jun 9.
5
[Expression and clinical significance of certain apoptosis and angiogenesis factors in hepatocellular carcinoma].[某些凋亡和血管生成因子在肝细胞癌中的表达及临床意义]
Zhonghua Wai Ke Za Zhi. 2006 Dec 1;44(23):1626-30.
6
Multicenter Study of Staging and Therapeutic Predictors of Hepatocellular Carcinoma Recurrence Following Transplantation.多中心研究:肝移植后肝细胞癌复发的分期和治疗预测因子。
Liver Transpl. 2018 Sep;24(9):1233-1242. doi: 10.1002/lt.25194.
7
Examinations of Factors Influencing Survival of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest.影响肝细胞癌肝移植生存因素的研究:来自布达佩斯的单中心经验
Transplant Proc. 2015 Sep;47(7):2201-6. doi: 10.1016/j.transproceed.2015.07.026.
8
Post-transplant infection improves outcome of hepatocellular carcinoma patients after orthotopic liver transplantation.肝移植后感染可改善原位肝移植后肝细胞癌患者的预后。
World J Gastroenterol. 2019 Oct 7;25(37):5630-5640. doi: 10.3748/wjg.v25.i37.5630.
9
Neoadjuvant Locoregional Therapy and Recurrent Hepatocellular Carcinoma after Liver Transplantation.肝移植术后新辅助局部区域治疗与复发性肝细胞癌
J Am Coll Surg. 2017 Jul;225(1):28-40. doi: 10.1016/j.jamcollsurg.2017.03.015. Epub 2017 Apr 9.
10
Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation.米兰标准以外的肝细胞癌的外科治疗。肝切除、挽救性移植和原位肝移植的结果。
Ann Surg Oncol. 2008 May;15(5):1383-91. doi: 10.1245/s10434-008-9851-z. Epub 2008 Mar 5.

引用本文的文献

1
P2X7 receptor promotes the growth and metastasis of gastric cancer by activating P13/AKT/GSK-3 beta signaling (experimental research).P2X7受体通过激活PI3/AKT/GSK-3β信号通路促进胃癌的生长和转移(实验研究)。
Int J Surg. 2025 Jun 1;111(6):3752-3766. doi: 10.1097/JS9.0000000000002406. Epub 2025 Apr 22.
2
MRI Radiomics Combined with Clinicopathological Factors for Predicting 3-Year Overall Survival of Hepatocellular Carcinoma After Hepatectomy.MRI影像组学联合临床病理因素预测肝癌肝切除术后3年总生存率
J Hepatocell Carcinoma. 2024 Jul 18;11:1445-1457. doi: 10.2147/JHC.S464916. eCollection 2024.
3

本文引用的文献

1
Aberrant MCT4 and GLUT1 expression is correlated with early recurrence and poor prognosis of hepatocellular carcinoma after hepatectomy.异常的 MCT4 和 GLUT1 表达与肝癌切除术后早期复发和预后不良相关。
Cancer Med. 2018 Nov;7(11):5339-5350. doi: 10.1002/cam4.1521. Epub 2018 Oct 10.
2
Long-term outcome of living donor liver transplantation for patients with alcoholic liver disease.酒精性肝病患者活体肝移植的长期预后
Transplant Proc. 2014 Apr;46(3):761-6. doi: 10.1016/j.transproceed.2013.12.032.
3
Meta-analysis of the prognostic and diagnostic significance of serum/plasma osteopontin in hepatocellular carcinoma.
Efficacy and safety analysis of PD-1 combined with regorafenib in the treatment of advanced hepatocellular carcinoma.
PD-1联合瑞戈非尼治疗晚期肝细胞癌的疗效与安全性分析
Am J Transl Res. 2024 Jun 15;16(6):2554-2562. doi: 10.62347/IIHG2242. eCollection 2024.
4
CircRNA hsa_circ_0069,399 as a potential clinical prognostic marker in laryngeal squamous cell carcinoma.环状RNA hsa_circ_0069399作为喉鳞状细胞癌潜在的临床预后标志物
Heliyon. 2024 May 25;10(11):e31969. doi: 10.1016/j.heliyon.2024.e31969. eCollection 2024 Jun 15.
5
Role of the Clinical Features and MRI Parameters on Ki-67 Expression in Hepatocellular Carcinoma Patients: Development of a Predictive Nomogram.肝细胞癌患者临床特征和 MRI 参数对 Ki-67 表达的作用:预测列线图的建立。
J Gastrointest Cancer. 2024 Sep;55(3):1069-1078. doi: 10.1007/s12029-024-01051-5. Epub 2024 Apr 9.
6
The influencing factors for tumor thrombus in patients with hepatocellular carcinoma.肝细胞癌患者肿瘤血栓的影响因素
J Gastrointest Oncol. 2024 Feb 29;15(1):415-424. doi: 10.21037/jgo-23-983. Epub 2024 Feb 23.
7
Combined utility of Ki-67 index and tumor grade to stratify patients with pancreatic ductal adenocarcinoma who underwent upfront surgery.Ki-67 指数与肿瘤分级联合用于分层接受直接手术的胰腺导管腺癌患者。
BMC Surg. 2023 Dec 8;23(1):370. doi: 10.1186/s12893-023-02256-4.
8
Kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study.肾型谷氨酰胺酶是肝细胞癌诊断和预后的生物标志物:一项前瞻性研究。
BMC Cancer. 2023 Nov 9;23(1):1081. doi: 10.1186/s12885-023-11601-y.
9
Serum VEGF levels as a predictor of recurrence in patients with advanced‑stage esophageal squamous cell carcinoma following curative esophagectomy followed by chemotherapy or concurrent radiotherapy.血清血管内皮生长因子水平作为晚期食管鳞状细胞癌患者根治性食管切除术后化疗或同步放疗后复发的预测指标。
Mol Clin Oncol. 2023 Sep 15;19(5):86. doi: 10.3892/mco.2023.2682. eCollection 2023 Nov.
10
Mutational Landscape and Precision Medicine in Hepatocellular Carcinoma.肝细胞癌的突变图谱与精准医学
Cancers (Basel). 2023 Aug 23;15(17):4221. doi: 10.3390/cancers15174221.
血清/血浆骨桥蛋白在肝细胞癌中的预后及诊断意义的Meta分析
J Clin Gastroenterol. 2014 Oct;48(9):806-14. doi: 10.1097/MCG.0000000000000018.
4
Correlation and prognostic value of osteopontin and Bcl-2 in hepatocellular carcinoma patients after curative resection.骨桥蛋白和 Bcl-2 在肝癌患者根治性切除术后的相关性及其预后价值。
Oncol Rep. 2013 Dec;30(6):2795-803. doi: 10.3892/or.2013.2737. Epub 2013 Sep 19.
5
Osteopontin: Versatile modulator of liver diseases.骨桥蛋白:肝脏疾病的多功能调节剂。
Hepatol Res. 2014 Jan;44(1):22-30. doi: 10.1111/hepr.12166. Epub 2013 Jun 20.
6
Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis.TP53 改变与肝细胞癌患者预后不良相关:系统评价和荟萃分析的证据。
Eur J Cancer. 2012 Oct;48(15):2328-38. doi: 10.1016/j.ejca.2012.03.001. Epub 2012 Mar 27.
7
Serum HIF-1alpha and VEGF levels pre- and post-TACE in patients with primary liver cancer.原发性肝癌患者经肝动脉化疗栓塞术(TACE)前后血清缺氧诱导因子-1α(HIF-1α)和血管内皮生长因子(VEGF)水平
Chin Med Sci J. 2011 Sep;26(3):158-62. doi: 10.1016/s1001-9294(11)60041-2.
8
HCC and angiogenesis: possible targets and future directions.肝细胞癌和血管生成:可能的靶点和未来方向。
Nat Rev Clin Oncol. 2011 May;8(5):292-301. doi: 10.1038/nrclinonc.2011.30. Epub 2011 Mar 8.
9
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.2008 年全球癌症负担估计值:GLOBOCAN 2008。
Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.
10
Global cancer statistics.全球癌症统计数据。
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4.